Content matching 'msc'
Webinar Q and A transcription: ‘Gene-modified mesenchymal stem cells as a potential treatment for Huntington's disease: preparing for a planned Phase I clinical trial’
Gene-modified mesenchymal stem cells as a potential treatment for Huntington's disease: preparing for a planned Phase I clinical trial
The Ottawa Hospital leads first Canadian clinical trial of mesenchymal stem cell therapy for multiple sclerosis.
Limited funding: The funds for this post are available until 31 January 2018 in the first instance. Three UK Research Councils; Biotechnology and Biological Sciences Research Council, Engineering and Physical Sciences Research Council and the Medical Research Council have invested £25m in research and equipment to support development of the UK Regenerative Medicine Platform (UKRMP www.ukrmp.org.uk). The Pluripotent Stem Cell Platform (PSCP) is one of five Hubs funded by the UKRMP to tackle critical challenges in developing new regenerative treatments from discoveries made in the laboratory. PSCP brings together researchers from several institutions to develop the processes needed to take pluripotent stem cells from laboratory-based research to the commercial manufacture of safe, effective and reproducible products for use in regenerative medicine.
Understanding Good Manufacturing Practice and how Biological Industries can support cell therapy development